Quanterix (NASDAQ:QTRX) versus FluoroPharma Medical (OTCMKTS:FPMI) Critical Comparison

FluoroPharma Medical (OTCMKTS:FPMI) and Quanterix (NASDAQ:QTRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of recent ratings for FluoroPharma Medical and Quanterix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FluoroPharma Medical	0	0	0	0	0.00
Quanterix	1	2	0	0	1.67

Quanterix has a consensus target price of $6.00, indicating a potential upside of 81.82%. Given Quanterix’s stronger consensus rating and higher possible upside, analysts clearly believe Quanterix is more favorable than FluoroPharma Medical.

Valuation and Earnings

This table compares FluoroPharma Medical and Quanterix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FluoroPharma Medical	N/A	N/A	N/A	N/A	N/A
Quanterix	$138.90 million	1.12	-$107.15 million	($2.52)	-1.31

FluoroPharma Medical has higher earnings, but lower revenue than Quanterix.

Insider and Institutional Ownership

86.5% of Quanterix shares are owned by institutional investors. 36.9% of FluoroPharma Medical shares are owned by company insiders. Comparatively, 6.8% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

FluoroPharma Medical has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Profitability

This table compares FluoroPharma Medical and Quanterix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FluoroPharma Medical	N/A	N/A	N/A
Quanterix	-77.14%	-23.96%	-17.86%

Summary

Quanterix beats FluoroPharma Medical on 5 of the 9 factors compared between the two stocks.

About FluoroPharma Medical

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.